相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings
Zachary R. Hitchcock et al.
JOURNAL OF PHARMACY PRACTICE (2023)
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages
Haithuy Pham et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2022)
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage
Mark L. Vestal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2022)
2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association
Steven M. Greenberg et al.
STROKE (2022)
Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin
Megan Heath et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2022)
Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage A Systematic Review and Meta-analysis
Rahul Chaudhary et al.
JAMA NETWORK OPEN (2022)
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
Olivia S. Costa et al.
CRITICAL CARE (2022)
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between-subject variation
Soren Risom Kristensen et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)
Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants
Ilanit Zada et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2021)
Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study
H. Andrew Wilsey et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2021)
Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Matthew J. Korobey et al.
NEUROCRITICAL CARE (2021)
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
Castillo Renee et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients
Emily A. Highsmith et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage
Abdalla A. Ammar et al.
NEUROCRITICAL CARE (2021)
Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
Subhajit Ghosh et al.
PLOS ONE (2021)
A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
Guido Willekens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model
Farahnaz Rayatdoost et al.
ANESTHESIOLOGY (2021)
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants
Antonio Gomez-Outes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
Victoria M. Stevens et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2021)
Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: An observational study
Smrithi Sukumar et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series
Tessa R. Reynolds et al.
JOURNAL OF PHARMACY PRACTICE (2021)
A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage
Karen Berger et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2020)
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Rahul Chaudhary et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel
Christopher W. Baugh et al.
ANNALS OF EMERGENCY MEDICINE (2020)
Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients
Teresa A. Allison et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2020)
Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage
Jennifer A. Frontera et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Factor Xa Inhibitor-Related Intracranial Hemorrhage Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates
Nicholas G. Panos et al.
CIRCULATION (2020)
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
Megan E. Barra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate
Louis Lipari et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2020)
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
David J. Seiffge et al.
ANNALS OF NEUROLOGY (2019)
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
Melanie N. Smith et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: Implications for trauma and acute care surgery
Joao D. Dias et al.
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY (2019)
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors
Oliver Grottke et al.
ANESTHESIOLOGY (2019)
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment
John W. Eikelboom et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage
Daniel Dybdahl et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2019)
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
Deepa R. J. Arachchillage et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves
Vincenzo Russo et al.
CLINICAL THERAPEUTICS (2019)
Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
Marwan Sheikh-Taha
INTERNAL AND EMERGENCY MEDICINE (2019)
Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma
Markus Honickel et al.
TRANSFUSION (2019)
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Adam Cuker et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
Fakiha Siddiqui et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis
Siavash Piran et al.
BLOOD ADVANCES (2019)
The Double Hazard of Bleeding and Thrombosis in Hemostasis From a Clinical Point of View: A Global Assessment by Rotational Thromboelastometry (ROTEM)
Olga Meltem Akay
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals
M. Santibanez et al.
JOURNAL OF CRITICAL CARE (2018)
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Jing Tao et al.
JOURNAL OF INTENSIVE CARE (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
Daniel M. Witt et al.
BLOOD ADVANCES (2018)
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature
Joseph R. Shaw et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
Maureane Hoffman et al.
INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE (2018)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
Y. Song et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Bethany T. Samuelson et al.
CHEST (2017)
Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
Herbert Schoechl et al.
ANESTHESIA AND ANALGESIA (2017)
Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma
Markus Honickel et al.
ANESTHESIOLOGY (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate
Stefano Barco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
S. Nagalla et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
The management of antithrombotic agents for patients undergoing GI endoscopy
Ruben D. Acosta et al.
GASTROINTESTINAL ENDOSCOPY (2016)
Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model
Markus Honickel et al.
ANESTHESIOLOGY (2015)
Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage
Eva Herzog et al.
ANESTHESIOLOGY (2015)
Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
Maureane Hoffman et al.
ANESTHESIOLOGY (2015)
Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates - In Vitro Studies With Steady and Circulating Human Blood -
Gines Escolar et al.
CIRCULATION JOURNAL (2015)
Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage
E. Herzog et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers
Y. W. Cheung et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial
Joshua N. Goldstein et al.
LANCET (2015)
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab
Markus Honickel et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Correlation of Coagulation Markers and 4F-PCC-Mediated Reversal of Rivaroxaban in a Rabbit Model of Acute Bleeding
Eva Herzog et al.
THROMBOSIS RESEARCH (2015)
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors
Ramesh Grandhi et al.
WORLD NEUROSURGERY (2015)
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
Hamim Zahir et al.
CIRCULATION (2015)
Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders
Omid R. Zekavat et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2014)
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
M. Levi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro
Elisabeth Perzborn et al.
THROMBOSIS RESEARCH (2014)
Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model
Eva Herzog et al.
THROMBOSIS RESEARCH (2014)
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Oliver Grottke et al.
CRITICAL CARE (2014)
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study
Ravi Sarode et al.
CIRCULATION (2013)
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban
J. Dinkelaar et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu et al.
NATURE MEDICINE (2013)
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
Anne Godier et al.
ANESTHESIOLOGY (2012)
New Antithrombotic Drugs Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Jeffrey I. Weitz et al.
CHEST (2012)
Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Anne Holbrook et al.
CHEST (2012)
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
I. Pragst et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
Raphael Marlu et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice
Thibaut Desmettre et al.
CRITICAL CARE (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers
Saskia Kuipers et al.
BLOOD (2009)
Thrombin generation testing in routine clinical practice: are we there yet?
J. J. van Veen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition
R Luddington et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Risk factors for venous thromboembolism
FA Anderson et al.
CIRCULATION (2003)
分享论文
